|
EMA Calls for Stepwise Approach to Biosimilar Monoclonal Antibodies
Developers of biosimilar monoclonal antibodies (mAb) must conduct nonclinical and clinical studies that compare the biosimilars with the original mAb to detect any relevant differences between the two products, according to a final European Medicines Agency (EMA) guideline.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives